Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
COX-2/5-LOX Inhibitor
Tebufelone is a selective dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO). It exhibits significant anti-inflammatory, analgesic, and antipyretic properties, making it useful for research into inflammatory pathways. This compound is valuable for studying the roles of COX-2 and 5-LO in various biological processes and assessing novel therapeutic strategies for inflammatory diseases. -
Dual COX/5-LOX Inhibitor
ER-34122 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO). This compound exhibits significant anti-inflammatory activity, making it valuable for research into inflammation-related pathways. ER-34122 is particularly relevant for studies investigating the interplay between COX and 5-LO pathways in various disease models and therapeutic contexts. -
5-LO/PGE2 Inhibitor
Canniprene is a potent inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase/microsomal prostaglandin E2 synthase (PGE2), with IC50 values of 0.4 μM and 10 μM, respectively. Derived from Cannabis sativa, Canniprene modifies the biosynthesis of inflammatory eicosanoids and prostaglandins, making it a valuable tool for researching inflammation and related pathways. Its unique mechanism of action positions Canniprene as a potential candidate for studying inflammatory diseases and therapeutic interventions targeting lipid mediators. -
TXA2/5-Lipoxygenase Inhibitor
CV-6504 is a dual inhibitor targeting thromboxane A2 (TXA2) synthase and 5-lipoxygenase. This compound demonstrates significant biological activity by scavenging reactive oxygen species (ROS) and exhibiting antitumor properties. CV-6504 is applicable in research focused on cancer, inflammation, and cardiovascular diseases, providing valuable insights into therapeutic strategies and molecular mechanisms. -
5-Lipoxygenase/Thromboxane Synthase Inhibitor
E 3040 is an orally active inhibitor of both 5-lipoxygenase and thromboxane synthase, key enzymes involved in inflammatory processes. This dual inhibition provides significant anti-inflammatory activity, making E 3040 a valuable reagent for research into inflammatory diseases and related pathways. Its unique mechanism can facilitate studies on the modulation of leukotrienes and thromboxanes in various biological contexts. -
PDE2 Inhibitor
ND-7001 is a potent inhibitor of phosphodiesterase 2 (PDE2) with an IC50 value of 0.05 μM, demonstrating significant selectivity against PDE3 and PDE4. This compound effectively elevates cGMP levels in primary neuronal cultures derived from rat cerebral cortical neurons, contributing to its role in modulating neuronal signaling. ND-7001 is primarily utilized in research focused on anxiety disorders and neuropharmacology, highlighting its potential for evaluating anxiolytic mechanisms. -
5-LO/TXA2 Inhibitor
E-6700 is a potent inhibitor of 5-lipoxygenase (5-LO) and thromboxane A2 (TXA2) synthetase, with IC50 values of 16.3 μM and 0.026 μM, respectively. This compound effectively inhibits the production of leukotriene B4 (LTB4) and thromboxane B2 (TXB2). E-6700 is suitable for applications in anti-inflammatory research, providing a valuable tool for investigating pathways associated with inflammatory responses. -
KRAS-PDEδ Interaction Inhibitor
Atrovastatin-PEG3-FITC is a KRAS-PDEδ interaction inhibitor that serves as a valuable tool in the study of KRAS signaling pathways. This compound can function as a ligand in fluorescence anisotropy assays, enabling researchers to investigate protein-protein interactions and their implications in cancer biology. Its application aids in understanding the role of KRAS in various malignancies and exploring potential therapeutic interventions. -
MAO A Inhibitor
MD 770222 is a selective and reversible inhibitor of monoamine oxidase A (MAO A). As a major O-demethyl metabolite of Cimoxatone, it exhibits notable inhibitory activity, albeit with reduced potency compared to its parent compound. This reagent is valuable in research focused on neurotransmitter modulation, neuropsychiatric disorders, and the understanding of MAO A's role in various biological processes. -
Lipoxygenase Inhibitor
Umbelliprenin is a prenylated coumarin that functions as a lipoxygenase inhibitor. It exhibits significant antioxidant properties along with anticancer, anti-inflammatory, and immunomodulatory activities. This compound effectively suppresses nitric oxide production in inflammatory macrophages, as well as inhibiting the expression of inducible nitric oxide synthase (iNOS). Umbelliprenin holds promise for research applications in the fields of inflammation, cancer biology, and immunology. -
α-Glucosidase Inhibitor
Isosojagol is an α-Glucosidase inhibitor with an IC50 of 32.2 μM, demonstrating significant potential in modulating carbohydrate metabolism. Isolated from the roots of Dolichos trilobus, Isosojagol exhibits anti-inflammatory properties by inhibiting LPS-induced nitric oxide production in RAW264.7 cells. This reagent is relevant for research into fracture healing, soft tissue injuries, and rheumatoid arthritis, providing a valuable tool for understanding the underlying biological mechanisms. -
IDO1 Inhibitor
VS-15 is an IDO1 inhibitor that selectively binds to the heme-free form of IDO1, interrupting its enzymatic activity. This compound has been linked to the reduction of nitric oxide (NO) production, suggesting additional broad-spectrum inhibitory effects on iNOS. VS-15 is primarily utilized in research focused on immunomodulation and cancer therapy, making it a valuable tool for studies investigating the role of tryptophan metabolism in immune responses. -
5-LO/mPGES-1 Inhibitor
5-LO/mPGES1-IN-1 is a dual inhibitor of 5-lipoxygenase (5-LO) and microsomal prostaglandin E2 synthase-1 (mPGES-1), exhibiting IC50 values of 0.3 μM and 0.4 μM, respectively. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research in inflammatory pathways. Applications include studies focused on the modulation of inflammatory responses, providing insights into potential therapeutic strategies for related diseases. -
TrxR2 Inhibitor
TrxR2-IN-1 is a selective inhibitor of thioredoxin reductase 2 (TrxR2) with an IC50 value of 0.83 μM. This compound accumulates in mitochondria, disrupts mitochondrial function and membrane potential, and enhances reactive oxygen species (ROS) production. It activates ASK1-mediated caspase-dependent apoptosis, induces G2/M cell cycle arrest, and reduces cancer cell migration. TrxR2-IN-1 is valuable for investigating hepatocellular carcinoma and related apoptotic pathways in cancer research. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-2 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). This benzothiophen-2-yl pyrazole carboxylic acid derivative demonstrates significant analgesic and anti-inflammatory properties, exhibiting COX-2 inhibitory activity with an IC50 of 0.01 μM and 5-LOX inhibitory activity with an IC50 of 1.78 μM. COX-2/5-LOX-IN-2 is a valuable tool for research applications aimed at understanding and modulating inflammatory pathways. -
CO/5-LO Inhibitor
P-8977 is a potent dual inhibitor of cyclooxygenase (CO) and 5-lipoxygenase (5-LO) with an IC50 of 0.01 µM and 0.53 µM, respectively. This compound exhibits significant anti-inflammatory activity, demonstrated by its ability to reduce ear edema. P-8977 is valuable for research focused on inflammatory skin conditions and their underlying biochemical mechanisms. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-5 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX). This compound effectively attenuates lipopolysaccharide-induced NF-κB activation in RAW 264.7 macrophages, highlighting its role in modulating inflammatory responses. COX-2/15-LOX-IN-5 exhibits significant anti-inflammatory and antioxidant properties, making it a valuable tool for research into inflammatory diseases and other related biological processes. -
Lipoxygenase/COX Inhibitor
SKF-105809 is a dual inhibitor of lipoxygenase and cyclooxygenase (COX), targeting key enzymes involved in the inflammatory pathway. This compound demonstrates a significant reduction in edema and inflammatory cell infiltration in murine models of ear, paw, and peritoneal inflammation. Additionally, SKF-105809 reduces the production of acute-phase reactive proteins in models of arthritis and exhibits analgesic effects in abdominal contraction assays while preventing ulceration. Its applications extend to the study of inflammatory and immune system disorders, including peritonitis and arthritis. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-1 is a dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX), exhibiting IC50 values of 10.65 μM for COX-1, 0.075 μM for COX-2, and 2.98 μM for 15-LOX. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its ability to modulate key enzymes involved in arachidonic acid metabolism positions COX-2/15-LOX-IN-1 as a promising candidate for therapeutic investigation in inflammatory conditions. -
5-LOX/COX-1 Inhibitor
Atractylochromene is a dual inhibitor targeting 5-lipoxygenase (5-LOX) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.6 μM and 3.3 μM, respectively. This compound serves as a valuable tool in research related to inflammatory pathways and can facilitate the study of related conditions influenced by leukotrienes and prostaglandins. Its inhibitory effects position Atractylochromene as a potential candidate for therapeutic exploration in inflammatory diseases. -
XO/COX/LOX Inhibitor
XO/COX/LOX-IN-1 is a potent inhibitor of xanthine oxidase, cyclooxygenases, and lipoxygenases. This compound exhibits significant anti-inflammatory activity, making it valuable for research in inflammation, cancer, and metabolic diseases. Its multifaceted inhibition profile positions XO/COX/LOX-IN-1 as a critical tool for exploring pathways involved in these pathological conditions. -
COX-2/LOX Inhibitor
COX-2/5-LOX-IN-4 is a potent dual inhibitor targeting both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), with IC50 values of 0.05 μM and 0.003 μM, respectively. By disrupting the arachidonic acid metabolism pathway, this compound effectively decreases the synthesis of prostaglandins and leukotrienes, leading to reduced inflammatory responses. In vivo studies using a rat ear edema model demonstrate its substantial anti-inflammatory activity, with intravenous doses resulting in up to 44% reduction in edema. COX-2/5-LOX-IN-4 is an important tool for investigating the mechanisms underlying inflammatory diseases. -
FAAH/COX Inhibitor
Carpro-AM1 is a dual-acting inhibitor targeting fatty acid amide hydrolase (FAAH) and selectively inhibiting cyclooxygenase (COX) enzymes. This compound exhibits an IC50 value of 94 nM for FAAH, demonstrating significant biological activity in regulating endocannabinoid signaling. Carpro-AM1 is suited for research applications focusing on pain management, inflammation, and the modulation of the endocannabinoid system. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-7 is a selective dual inhibitor targeting cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX) with IC50 values of 0.022 and 1.19 μM, respectively. It also demonstrates inhibition of COX-1 with an IC50 of 28.081 μM. This compound exhibits low cytotoxicity in human colorectal cancer cell lines (HT-29 and HCT116) with IC50 values exceeding 100 μM, and shows a non-ulcerogenic profile. COX-2/15-LOX-IN-7 is valuable for cancer research applications, facilitating the study of inflammatory pathways and therapeutic interventions. -
COX/5-LOX Inhibitor
CI-986 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), effectively preventing coronary vasoconstriction and the excessive production of leukotrienes, including LTB4 and LTC4. This compound exhibits notable anti-inflammatory and analgesic properties, making it a valuable tool for research into inflammation and cardiovascular diseases, including conditions like arthritis. CI-986's unique mechanism positions it as an important reagent in studies focused on the modulation of inflammatory pathways and vascular health. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-1 is a dual inhibitor targeting cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), represented as a benzothiophen-2-yl pyrazole carboxylic acid derivative. This compound exhibits significant analgesic and anti-inflammatory properties, demonstrating enhanced efficacy compared to traditional nonsteroidal anti-inflammatory drugs. COX-2/5-LOX-IN-1 displays potent inhibition of COX-1, COX-2, and 5-LOX, with IC50 values of 12.13, 0.4, and 4.96 μM, respectively, making it a valuable tool for research in pain and inflammation pathways. -
COX-2/5-LOX Inhibitor
Speranskoside is a dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase-15 (5-LOX), exhibiting an IC50 of 2.62 μg/mL for COX-2 and 5.51 μg/mL for 5-LOX. This compound demonstrates significant anti-inflammatory activity, making it valuable for the investigation of gastric ulcers and related disorders. Its unique mechanism of action provides a foundational tool for research into inflammatory pathways and therapeutic interventions. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-3 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase (5-LOX), exhibiting IC50 values of 45.73 µM for COX-1, 5.45 µM for COX-2, and 4.33 µM for 5-LOX. This compound is valuable for studying inflammatory diseases, as it effectively modulates the associated biochemical pathways. Its dual inhibition may provide insights into the complex roles of COX-2 and 5-LOX in mediating inflammatory responses. -
5-lipoxygenase Inhibitor
L-651896 is a potent inhibitor of 5-lipoxygenase, exhibiting significant anti-inflammatory and antiproliferative properties. By obstructing the production of leukotrienes and prostaglandins, L-651896 is useful in investigating skin diseases and various other inflammatory conditions. Its mechanism of action supports research aimed at understanding the role of lipid mediators in inflammatory pathways. -
5-lipoxygenase/ cyclooxygenase Inhibitor
PD 127443 is an inhibitor of both 5-lipoxygenase and cyclooxygenase, targeting critical enzymes involved in the inflammatory response. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research applications focused on understanding the mechanisms of inflammation and exploring potential therapeutic interventions in inflammatory diseases. -
COX/5-LOX Inhibitor
ZLJ-6 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), demonstrating potent oral bioactivity. With IC50 values of 0.73 μM for COX-1, 0.31 μM for COX-2, and 0.99 μM for 5-LOX, ZLJ-6 exhibits significant anti-inflammatory and analgesic properties. This compound is suitable for research applications aimed at investigating inflammatory pathways and potential therapeutic interventions. -
5-LOX/COX Inhibitor
(-)-Bornyl ferulate serves as a dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), displaying IC50 values of 10.4 μM and 12.0 μM, respectively. This compound demonstrates significant anti-inflammatory potential, making it useful for research focused on inflammation-related pathways and conditions. Its ability to modulate leukotriene and prostaglandin synthesis positions it as a valuable tool in the study of various inflammatory diseases and therapeutic interventions. -
CypD Inhibitor
CypD-IN-4 is a potent and selective inhibitor of cyclophilin D (CypD), exhibiting high affinity with an IC50 of 0.057 μM. This compound is valuable in researching various conditions related to oxidative stress, neurodegenerative diseases, liver dysfunction, aging processes, autophagy, and diabetes. CypD-IN-4 facilitates the exploration of CypD's role in these pathologies, providing insights into potential therapeutic strategies. -
CypD Inhibitor
CypD-IN-3 is a potent and selective inhibitor of cyclophilin D (CypD), demonstrating high affinity with an IC50 value of 0.01 μM. This compound is valuable for studying a range of biological processes and diseases, including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy, and diabetes. Its specificity towards CypD makes it an important tool for elucidating the role of this target in various cellular functions and pathological conditions. -
CypE Inhibitor
CypE-IN-1 is a highly potent and selective inhibitor of cyclophilin E (CypE), exhibiting an IC50 of 0.013 μM and a Ki value of 0.072 μM. This compound is valuable for investigating the role of CypE in various pathological conditions, including oxidative stress, neurodegenerative diseases, liver disorders, aging processes, autophagy, and diabetes. Researchers can utilize CypE-IN-1 to explore therapeutic strategies targeting CypE-related pathways. -
ALDH Inhibitor
4-Diethylaminobenzaldehyde is a reversible inhibitor of aldehyde dehydrogenases (ALDHs), exhibiting a Ki value of 4 nM specifically for ALDH1. This compound has demonstrated significant anti-androgenic activity with an IC50 of 1.71 μM. Its inhibitory effects on ALDH activities make it a valuable tool in biological research, particularly in studies focused on metabolic processes and hormonal regulation. -
ALDH1 Inhibitor
ABD-3001 is a selective inhibitor of aldehyde dehydrogenase 1 (ALDH1). It has demonstrated potential in the study of refractory or relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. This compound may serve as a valuable tool for elucidating the role of ALDH1 in hematological malignancies and developing targeted therapies. -
ALDH1a2 Inhibitor
Win 18446 is a selective inhibitor of the testes-specific enzyme ALDH1a2, exhibiting an IC50 of 0.3 μM. This compound effectively reverses spermatogenesis across various species and disrupts the biosynthesis of retinoic acid from retinol within the testes. It is valuable for research applications focused on reproductive biology and the modulation of retinoid signaling pathways. -
ALDH18A1 Inhibitor
YG1702 is a selective inhibitor of ALDH18A1, a key enzyme involved in the biosynthesis of polyamines. This compound has demonstrated significant inhibitory effects on the proliferation of MYCN-amplified neuroblastoma cells and leads to down-regulation of MYCN expression. YG1702 binds to ALDH18A1 with high affinity, suggesting it may alter the enzyme’s activity and function. This reagent is valuable for research applications focused on neuroblastoma and cellular growth regulation. -
ALDH-2 Inhibitor
CVT-10216 is a highly selective, reversible inhibitor of aldehyde dehydrogenase-2 (ALDH-2), demonstrating an IC50 of 29 nM. This compound also exhibits inhibitory effects on ALDH-1 with an IC50 of 1.3 μM. CVT-10216 has been shown to reduce excessive alcohol consumption in alcohol-preferring rat models and exhibits anxiolytic properties, making it valuable for research into alcohol use disorders and anxiety-related conditions. -
ALDH3A1 Inhibitor
ALDH3A1-IN-3 is a selective inhibitor of the enzyme ALDH3A1, exhibiting a Ki value of 4.7 μM and an IC50 value of 16 μM. This compound shows no inhibitory activity against ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2 in vitro. ALDH3A1-IN-3 is suitable for investigations in cellular oxidation processes and cancer research, making it a valuable tool for studying the role of ALDH3A1 in various biological contexts. -
ALDH3A1 Inhibitor
ALDH3A1-IN-1 is a potent inhibitor of the aldehyde dehydrogenase 3A1 (ALDH3A1) enzyme, exhibiting an IC50 of 1.61 μM. This compound demonstrates superior efficacy compared to DEAB in targeting patient-derived primary prostate tumor epithelial cells, both as a standalone treatment and in combination with docetaxel. ALDH3A1-IN-1 is a valuable tool for investigating ALDH3A1's role in cancer biology and therapeutic resistance. -
ALDH1B1 Inhibitor
IGUANA-1 is a selective inhibitor of ALDH1B1, exhibiting potent activity against this target. It demonstrates minimal mitochondrial toxicity, making it suitable for various experimental applications. Its antitumor properties position IGUANA-1 as a valuable compound for cancer research and drug development. -
ALDH1A3 Inhibitor
ALDH1A3-IN-3 is a potent inhibitor of aldehyde dehydrogenase 1A3 (ALDH1A3), exhibiting an IC50 of 0.26 μM. This compound shows potential as a research tool for studying prostate cancer and can aid in understanding the role of ALDH1A3 in tumor biology. However, it functions as a substrate for ALDH3A1, which may limit its specificity as a selective inhibitor. -
ALDH1A3 Inhibitor
ALDH1A3-IN-1 is a potent inhibitor of aldehyde dehydrogenase 1A3 (ALDH1A3), exhibiting an IC50 value of 0.63 μM and a Ki of 0.46 μM. This compound plays a significant role in cancer research, particularly in the study of prostate cancer, by modulating metabolic pathways associated with tumor progression. Researchers can utilize ALDH1A3-IN-1 to explore the implications of ALDH1A3 inhibition in cellular and molecular contexts pertaining to oncology. -
ALDH1A1 Inhibitor
CM037 is a highly selective and competitive inhibitor of the enzyme ALDH1A1, with an IC50 of 4.6 μM. By blocking the catalytic activity of ALDH1A1, CM037 inhibits the activation of the HIF-1α/VEGF signaling pathway. This reagent is primarily utilized to investigate the role of ALDH1A1 in the regulation of cancer stem cells and angiogenesis, particularly in breast cancer models, highlighting its potential to obstruct tumor angiogenesis and stem cell properties. -
ALDH3A1 Inhibitor
EN40 is a selective inhibitor of aldehyde dehydrogenase 3A1 (ALDH3A1), functioning as a covalent ligand with an IC50 value of 2 µM. This compound demonstrates significant inhibitory activity, making it a valuable tool for research focused on cellular metabolism and oxidative stress. Its application extends to the study of various diseases where ALDH3A1 plays a role, providing insights into potential therapeutic interventions. -
ALDH1A Inhibitor
CM010 is a selective inhibitor of the aldehyde dehydrogenase 1A (ALDH1A) family, exhibiting IC50 values of 1700 nM, 740 nM, and 640 nM for ALDH1A1, ALDH1A2, and ALDH1A3, respectively. This compound does not inhibit other members of the ALDH family, making it a valuable tool for specific enzyme studies. CM010 demonstrates potential in regulating metabolic processes and exhibits anti-cancer activity, making it relevant for cancer research applications. -
ALDH1A3 Inhibitor
ALDH1A3-IN-2 is a selective inhibitor of aldehyde dehydrogenase 1A3 (ALDH1A3) with an IC50 of 1.29 μM. This compound demonstrates significant potential for studying the role of ALDH1A3 in various malignancies, particularly in prostate cancer where ALDHs are frequently overexpressed. ALDH1A3-IN-2 can be utilized in research focusing on cancer pathways and therapeutic strategies targeting ALDH-related enzymatic activity. -
ALDH1A3 Inhibitor
MCI-INI-3 is a selective competitive inhibitor of human ALDH1A3, exhibiting a Ki value of 0.55 μM for ALDH1A3 and a Ki value of 78.2 μM for ALDH1A1. This compound effectively disrupts retinoic acid biosynthesis, leading to a reduction in viability of glioblastoma stem cells GSC-83 and GSC-326. MCI-INI-3 is a valuable tool for research focused on cancer biology and the therapeutic targeting of glioblastoma.
